A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
Condition: Asthma Interventions: Drug: FF/UMEC/VI (100/31.25/25) mcg; Drug: FF/UMEC/VI (100/62.5/25) mcg; Drug: FF/UMEC/VI (200/31.25/25) mcg; Drug: FF/UMEC/VI (200/62.5/25) mcg; Drug: FF/VI (100/25) mcg; Drug: FF/VI (200/25) mcg; Drug: Fluticasone/salmeterol (FSC); Drug: Albuterol/salb utamol; Device: ELLIPTA DPI; Device: DISKUS DPI; Device: METERED-DOSE INHALER (MDI) Sponsor: GlaxoSmithKline Not yet recruiting - verified October 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials